Loading...
•
Dec 31, 2019
Ultragenyx Q4 2019 Earnings Report
Ultragenyx reported financial results for Q4 2019 and reaffirmed its financial guidance for 2020.
Key Takeaways
Ultragenyx reported total revenue of $35.6 million for the fourth quarter of 2019. The company's net loss for the quarter was $93.8 million, or $1.62 per share.
Total revenue for Q4 2019 was $35.6 million.
Crysvita revenue totaled $29.9 million, including $26.1 million in U.S. collaboration revenue and $2.2 million in European royalty revenue.
Mepsevii product revenue was $4.4 million.
Net loss for Q4 2019 was $93.8 million, or $1.62 per share.
Ultragenyx
Ultragenyx
Ultragenyx Revenue by Segment
Revenue by Segment
Crysvita Revenue
CapyFin.comMepsevii Revenue
CapyFin.com Forward Guidance
The company continues to expect Crysvita revenue in the Ultragenyx territories to be between $125 million and $140 million in 2020 and expects a more than 20 percent reduction in net cash burn in 2020 compared to 2019.